QIAGEN EPS - Earnings per Share 2010-2022 | QGEN

QIAGEN annual and quarterly earnings per share history from 2010 to 2022. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • QIAGEN EPS for the quarter ending September 30, 2022 was $0.36, a 36.84% decline year-over-year.
  • QIAGEN EPS for the twelve months ending September 30, 2022 was $2.01, a 21.48% decline year-over-year.
  • QIAGEN 2021 annual EPS was $2.21, a 44.44% increase from 2020.
  • QIAGEN 2020 annual EPS was $1.53, a 950% decline from 2019.
  • QIAGEN 2019 annual EPS was $-0.18, a 121.95% decline from 2018.
QIAGEN Annual EPS
2021 $2.21
2020 $1.53
2019 $-0.18
2018 $0.82
2017 $0.17
2016 $0.34
2015 $0.55
2014 $0.48
2013 $0.30
2012 $0.56
2011 $0.42
2010 $0.62
2009 $0.67
QIAGEN Quarterly EPS
2022-09-30 $0.36
2022-06-30 $0.42
2022-03-31 $0.67
2021-12-31 $0.56
2021-09-30 $0.57
2021-06-30 $0.52
2021-03-31 $0.56
2020-12-31 $0.91
2020-09-30 $0.07
2020-06-30 $0.38
2020-03-31 $0.17
2019-12-31 $0.21
2019-09-30 $-0.71
2019-06-30 $0.19
2019-03-31 $0.13
2018-12-31 $0.26
2018-09-30 $0.26
2018-06-30 $0.16
2018-03-31 $0.14
2017-12-31 $-0.18
2017-09-30 $0.21
2017-06-30 $0.06
2017-03-31 $0.08
2016-12-31 $0.03
2016-09-30 $0.15
2016-06-30 $0.09
2016-03-31 $0.07
2015-12-31 $0.21
2015-09-30 $0.15
2015-06-30 $0.11
2015-03-31 $0.08
2014-12-31 $0.09
2014-09-30 $0.15
2014-06-30 $0.15
2014-03-31 $0.10
2013-12-31 $0.27
2013-09-30 $0.18
2013-06-30 $-0.23
2013-03-31 $0.08
2012-12-31 $0.17
2012-09-30 $0.13
2012-06-30 $0.15
2012-03-31 $0.13
2011-12-31 $-0.01
2011-09-30 $0.16
2011-06-30 $0.15
2011-03-31 $0.13
2010-12-31 $0.16
2010-09-30 $0.16
2010-06-30 $0.17
2010-03-31 $0.15
2009-12-31 $0.19
2009-09-30 $0.19
2009-06-30 $0.16
2009-03-31 $0.13
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $11.249B $2.252B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00